NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 41.81.
| Share Price | ₹3,239.6 | Jul 21,2026 |
| Market Cap | ₹2,008.5 Cr | |
| Earnings-TTM | ₹48.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 41.81x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,008.5 Cr] as on Jul 21,2026
(/) Earnings [ ₹48.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 41.81x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 41.81 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 48.04 | 41.81 | 2,008.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 40.71 | 470,786.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 75.77 | 194,590.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 89.64 | 191,658.0 |
| CIPLA LTD | 3,869.79 | 29.91 | 115,728.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 24.30 | 100,708.0 |
| MANKIND PHARMA LTD | 1,926.41 | 55.26 | 106,460.0 |
| LUPIN LTD | 5,355.47 | 21.47 | 114,967.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.70 | 114,080.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 25.97 | 90,935.6 |
| LAURUS LABS LTD | 889.85 | 96.71 | 86,059.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 21.47x |
| Max industry PE | 96.71x |
| Median industry PE | 40.71x |
| Average industry PE | 47.66x |
You may also like the below Video Courses